CSL Behring Marks World Hemophilia Day with Factor IX Donation to World
Federation of Hemophilia

    
    Company to donate 1 million units of Hemophilia B medication via WFH's
    Global Alliance for Progress (GAP) program




    
</pre>
<p>KING OF PRUSSIA, Pa. and <span class="xn-location">MONTREAL</span>, <span class="xn-chron">April 16</span> /CNW/ -- Hemophilia B patients in the developing world will benefit from a recent donation of 1 million international units (IU) of factor IX medication made by CSL Behring to the World Federation of Hemophilia (WFH). The donation, channeled through WFH's <span class="xn-location">United Kingdom</span> chapter, marks World Hemophilia Day 2010 and will support WFH's progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program.</p>
<p/>
<p>The total value of the donation is estimated at <span class="xn-money">$700,000</span> (US) and is in addition to a <span class="xn-money">$2 million</span> donation of coagulation factor (to extend over a period of three years) that CSL Behring made to WFH last year.  The factor IX product is manufactured in the Kankakee, IL, USA facility of CSL Behring.  CSL Ltd., parent company to CSL Behring, is committed to contributing to the economic, social and environmental well-being of its communities.</p>
<p/>
<p>CSL Behring has also renewed its pledge to continue supporting the WFH with separate financial contributions totaling nearly <span class="xn-money">$1 million</span>, also over a period of three years.</p>
<p/>
<p>"As a long-standing contributor to GAP, CSL Behring is pleased and proud to increase our support of the World Federation of Hemophilia," said <span class="xn-person">Peter Turner</span>, President and Chief Executive Officer of CSL Behring. "WFH's efforts to bring about improvements and change in the delivery of healthcare services and medicines to hemophilia patients in areas of the world where the need is greatest is a mission that aligns closely with ours. We share a focus on serving patients with rare and serious bleeding disorders and continually seek ways to make large and positive differences for them and their communities."</p>
<p/>
<p>"The WFH relies on product donations in fulfilling its commitment to introduce clotting factor concentrates in developing countries where it might not otherwise be available," said <span class="xn-person">Mark Skinner</span>, President of the WFH. "In turn, these donations serve as a catalyst for improving the overall care of people with bleeding disorders in need. CSL Behring's generous and ongoing support enables WFH to deliver on that promise, leading to the creation of sustainable national hemophilia care programs that are a vital part of the global public health care system. We are grateful to all our industry partners who provide, among other resources, valuable and life-saving medicine, including CSL Behring's most recent donation of factor IX for the treatment of hemophilia B."</p>
<p/>
<p>Factor IX is an essential blood clotting factor. FIX is concentrated from donated blood or is manufactured using recombinant technology, and can be given to hemophiliacs to restore hemostasis.</p>
<pre>
    

    About the Global Alliance for Progress
    
</pre>
<p>The Global Alliance for Progress (GAP) is a 10-year healthcare development project, launched in 2003. GAP's goal is to greatly increase the diagnosis and treatment of people with hemophilia and other bleeding disorders in developing countries.</p>
<p/>
<p>The program aims to close the gap between the number of people born with hemophilia and those who reach adulthood, the gap between the estimated and actual number of people diagnosed with bleeding disorders, and the gap between the amount of treatment product needed versus what is available.</p>
<p/>
<p>GAP partners include CSL Behring, Baxter, Bayer, Biotest, the Irish Hemophilia Society, the Jan Willem Andre de la Porte Family Foundation, Pfizer, Talecris, and the World Health Organization (WHO).</p>
<p/>
<p>Sixteen countries have participated in GAP: <span class="xn-location">Armenia</span>, <span class="xn-location">Azerbaijan</span>, <span class="xn-location">Belarus</span>, <span class="xn-location">China</span>, <span class="xn-location">Ecuador</span>, <span class="xn-location">Egypt</span>, <span class="xn-location">Georgia</span>, <span class="xn-location">Jordan</span>, <span class="xn-location">Lebanon</span>, <span class="xn-location">Mexico</span>, <span class="xn-location">Philippines</span>, <span class="xn-location">Russia</span>, <span class="xn-location">Syria</span>, <span class="xn-location">Thailand</span>, and <span class="xn-location">Tunisia</span>. A GAP project in <span class="xn-location">Peru</span> has just been launched.</p>
<pre>
    

    About the World Federation of Hemophilia
    
</pre>
<p>The World Federation of Hemophilia (WFH) is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and related bleeding disorders.</p>
<p/>
<p>Since it was established in 1963, the WFH has grown into a truly global network with member organizations in 113 countries and official recognition from the World Health Organization. WFH works in partnership with healthcare professionals and people with hemophilia, governments and regulators, industry and foundations, to improve hemophilia care throughout the world. For more information, visit <a href="http://www.wfh.org">www.wfh.org</a>.</p>
<pre>
    

    About CSL Behring
    
</pre>
<p>CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.</p>
<p/>
<p>CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.</p>
<p/>
<p>CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in <span class="xn-location">Melbourne</span>, <span class="xn-location">Australia</span>. For more information, visit <a href="http://www.cslbehring.com">www.cslbehring.com</a>.</p>
<p/>
<p> </p>
<p> </p>
<pre>
    
    Contacts:
    World Federation of Hemophilia     CSL Behring
                                        Sheila A. Burke, Director, Public
    Sarah Ford, Communications Manager  Relations
    1 514 394-2822                     610-878-4209
    [email protected]                      [email protected]






    

For further information: Sarah Ford, Communications Manager, World Federation of Hemophilia, [phone], [email protected]; or Sheila A. Burke, Director, Public Relations, CSL Behring, [phone], [email protected] Web Site: http://www.cslbehring.com http://www.wfh.org